Eli Lilly is a global pharmaceutical company dedicated to discovering, developing, manufacturing, and marketing innovative medicines that address some of the world's most challenging health issues. The company focuses on areas such as diabetes, oncology, immunology, and neurodegenerative diseases, providing a wide range of treatments designed to improve patient outcomes and quality of life. Eli Lilly is committed to scientific advancement and works collaboratively with healthcare professionals and researchers to bring new therapies and solutions to market, ensuring access to life-saving medications for patients around the globe. Read More
As the curtain falls on another corporate earnings season, the S&P 500 has delivered a performance that has largely exceeded initial expectations, painting a picture of surprising corporate health amidst a complex economic landscape. Companies across various sectors have reported significant year-over-year profit and revenue growth, providing a much-needed
Shares of global pharmaceutical company Eli Lilly (NYSE:LLY)
jumped 3.1% in the afternoon session after the stock rebounded following a decline the previous week. The stock had dropped sharply the previous week after the company released its Q2 2025 earnings report. Although the company beat earnings and revenue expectations and raised its full-year guidance, the positive news was overshadowed by disappointing trial data for its oral weight-loss drug, orforglipron. The drug's trial results showed a weight loss of about 12%, which fell short of analyst expectations and the performance of some rival treatments.
The current upward movement can be seen as a "buy the dip" opportunity as investors are likely re-evaluating the stock's long-term potential.
Curious about the top performers within the S&P500 index in the middle of the day on Monday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.
A federal appeals court revived a lawsuit accusing Sanofi, Eli Lilly, Novo Nordisk, and AstraZeneca of conspiring to restrict 340B drug discounts for safety-net clinics, sending the case back to district court for further proceedings.
Eli Lilly and Company reported robust second-quarter 2025 results, wherein it beat estimates on both the top and bottom lines. However, shares of Eli Lilly stock tumbled 14%. Here are ETFs with exposure to Eli Lilly that may still be worth a look.
Trump’s plan to cover weight loss drugs under Medicaid programs and Medicare Part D plans to could be a major tailwind for LLY and NVO, despite tarrif threats.
The past week saw market turbulence, with President Trump's new gold tariffs, Eli Lilly's dramatic stock drop, a weakening jobs report fueling recession fears, and a divided Federal Reserve debating rate cuts.
After a dip last week, Wall Street rebounded as earnings remained strong. Tech stocks surged, but Eli Lilly struggled. Trump imposed tariffs on India and nominated Stephen Miran for Fed seat.
Wall Street has experienced a broadly positive day, marked by a resilient rally that has added over $1 trillion in market value. This surge in investor confidence is primarily driven by a confluence of strong corporate earnings, sustained momentum in the technology sector, and a perceived easing of anxieties related
Eli Lilly's orforglipron missed weight loss targets in a Phase 3 trial, but strong Q2 results and raised guidance highlight the company's growth strength.
Weight loss drug goliath Eli Lilly just tanked despite posting impressive Q2 results. See what drove the decline and whether the market reaction is overdone.
